Delphian Pharma Announces-Discovery of Novel Anti-Tumor Antimitotic Agents That Also Reverse Tumor Resistance
Posted on: Wednesday, 25 July 2007, 15:22 CDT
Scientists at Duquesne University and the Medical University of South Carolina report in the on line version of the Journal of Medicinal Chemistry (50,3290,2007) on novel compounds with potent anti-tumor activity, which are also active on cancer cells resistant to other anti-tumor agents. Many tumors develop resistance to chemotherapeutic agents such as paclitaxol by producing protein pumps, such as p-glycoprotein, which expel the cancer drugs which penetrate into the tumor cells. Thus, the level of cancer drug is reduced and the cancer cell escapes. The development of drug resistance is a critical event in cancer removing therapeutic options.
Detailed studies of the Duquesne compounds have shown that they, like Paclitaxol and Vincristine, disrupts tubulin which forms structural supports in the cell necessary for cell extension, migration and survival. The Duquesne compounds are not expelled by the pump protein, P- glycoprotein, and thus are active on drug resistant tumor cells. Unexpectedly, it was discovered that the Duquesne compounds restored the sensitivity of drug resistant cancer cells to other anticancer agents by inactivating P- glycoprotein. Compounds with such dual actions, i.e. cytotoxicity and the ability to reverse drug resistance, are unusual. The significance of the work is that the development of resistance to previously effective cancer chemotherapeutic agents is a major cause of death in cancer patients and new more effective drugs are needed to treat patients with drug resistant tumors.
Dr. Aleem Gangjee, Distinguished Professor of Medicinal Chemistry at Duquesne University explained that, "My group has been long interested in developing dual acting anticancer agents to enhance the effectiveness of cancer therapies. We have been successful in doing this with anti-folates, with anti-angiogenic agents and now with these anti-mitotic agents. We hope that this will start a new era in cancer research and hopefully treatment."
Duquesne University is located in Pittsburgh PA and has broad educational programs in liberal arts, in science, in health science and in business.
Delphian Pharmaceuticals, a San Francisco biotech company, has licensed the Duquesne technology and is developing a portfolio of duel action anti-cancer compounds. CEO Gary Hooper stated, "It is a pleasure to work with Dr. Gangjee and Duquesne in developing their platform of novel and promising therapeutic agents." Delphian's founder Dr. Kumar Gadamasetti, himself a medicinal chemist noted that, "Duquesne has one of the finest medicinal chemistry programs in the country."
Source: Business Wire
Related Articles
- Rosalind Franklin University of Medicine and Science First in Illinois to Equip Students With Computerized Diagnosis System
- Cell Therapeutics Acquires SMi, Gains Rights to Cancer Killing Agent
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- Anti-Drug Advertising Campaign a Failure, GAO Report Says
- Anti-Drug Group Fights Medical-Marijuana Bill
- Guatemala anti-drug chief arrested for smuggling
- Chile, Colombia Agree to Intensify Anti-Drug Cooperation
- Dear Pharmacist: It's Not 'Anti-Drug' to Advocate Consumer Caution
- Bush Anti-Drug Plan to Target Painkillers
- Bush Anti-Drug Plan to Target Pain Killers
 |
 |
User Comments (0)
RSS Feeds